PE20121519A1 - Compuestos de pirazol como antagonistas de crth2 - Google Patents

Compuestos de pirazol como antagonistas de crth2

Info

Publication number
PE20121519A1
PE20121519A1 PE2012001022A PE2012001022A PE20121519A1 PE 20121519 A1 PE20121519 A1 PE 20121519A1 PE 2012001022 A PE2012001022 A PE 2012001022A PE 2012001022 A PE2012001022 A PE 2012001022A PE 20121519 A1 PE20121519 A1 PE 20121519A1
Authority
PE
Peru
Prior art keywords
compounds
methylene
halogen
ethylene
alkyl
Prior art date
Application number
PE2012001022A
Other languages
English (en)
Inventor
Thorsten Oost
Ralf Anderskewitz
Dieter Wolfgang Hamprecht
Christoph Hoenke
Domnic Martyres
Wolfgang Rist
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42112128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121519(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20121519A1 publication Critical patent/PE20121519A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

SE REFIERE A COMPUESTOS DE PIRAZOL DE FORMULA (I) DONDE: W ES HIDROXICARBONILO, TETRAZOL-5-ILO 1,2,4-OXADIAZOL-5(4H)-ON-3-ILO, ENTRE OTROS; X ES UN RESTO CARBOCICLICO O HETEROCICLICO C6 SELECCIONADOS ENTRE FEN-1,4-ILENO, PIRIDIN-2,5-ILENO, ENTRE OTROS OPCIONALMENTE SUSTIUIDOS; Y ES H, ALQUILO C1-6, CICLOALQUILO C3-8, FENILO, ENTRE OTROS; L1 ES METILENO, ETILENO, ETENILENO O ACETILENO DONDE CADA ATOMO DE CARBONO EN METILENO O ETILENO ESTA OPCIONALMENTE SUSTITUIDO POR 1 O 2 RADICALES SELECCIONADOS ENTRE HIDROXI, HALOGENO, ENTRE OTROS; L2 ES METILENO O ETILENO EN LOS QUE CADA ATOMO DE CARBONO ESTA OPCIONALMENTE SUSTITUIDO POR 1 O 2 RADICALES SELECCIONADOS ENTRE HIDROXI, HALOGENO, ENTRE OTROS; L3 ES -CH=CH-, -C(O)-, ENTRE OTROS; R1 Y R2 SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO C1-6, ALQUENILO C2-6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO{3,5-DIMETIL-1-[4-(4-TRIFLUOROMETIL-BENZOILAMINO)-BENCIL]-1H-PIRAZOL-4-IL}-ACETICO; ACIDO 3-[1-(4-BENCILOXICARBONILAMINO-BENCIL)-3,5-DIMETIL-1H-PIRAZOL-4-IL]-PROPIONICO; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE CRTH2 SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS, GASTROINTESTINALES, INFLAMATORIAS, ALERGICAS
PE2012001022A 2010-01-27 2011-01-24 Compuestos de pirazol como antagonistas de crth2 PE20121519A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10151785 2010-01-27

Publications (1)

Publication Number Publication Date
PE20121519A1 true PE20121519A1 (es) 2012-12-02

Family

ID=42112128

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001022A PE20121519A1 (es) 2010-01-27 2011-01-24 Compuestos de pirazol como antagonistas de crth2

Country Status (37)

Country Link
US (1) US8791272B2 (es)
EP (1) EP2528901B9 (es)
JP (1) JP5658284B2 (es)
KR (2) KR101906791B1 (es)
CN (3) CN104829535A (es)
AP (1) AP3360A (es)
AR (1) AR080032A1 (es)
AU (1) AU2011209286B2 (es)
BR (1) BR112012018695A2 (es)
CA (1) CA2788224C (es)
CL (1) CL2012001836A1 (es)
CO (1) CO6511272A2 (es)
CY (1) CY1116641T1 (es)
DK (1) DK2528901T3 (es)
EA (1) EA022280B1 (es)
ES (1) ES2545865T3 (es)
GE (1) GEP20146177B (es)
HK (1) HK1176062A1 (es)
HR (1) HRP20150898T1 (es)
HU (1) HUE025318T2 (es)
IL (1) IL220208A (es)
MA (1) MA33937B1 (es)
MX (1) MX353000B (es)
MY (1) MY160036A (es)
NZ (1) NZ600637A (es)
PE (1) PE20121519A1 (es)
PL (1) PL2528901T3 (es)
PT (1) PT2528901E (es)
RS (1) RS54176B1 (es)
SG (1) SG182684A1 (es)
SI (1) SI2528901T1 (es)
TN (1) TN2012000371A1 (es)
TW (1) TWI499416B (es)
UA (1) UA110025C2 (es)
UY (1) UY33201A (es)
WO (1) WO2011092140A1 (es)
ZA (1) ZA201204335B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101906791B1 (ko) 2010-01-27 2018-10-11 베링거 인겔하임 인터내셔날 게엠베하 Ｃｒｔｈ２ 길항제로서의 피라졸 화합물
KR20130115311A (ko) * 2010-11-24 2013-10-21 알러간, 인코포레이티드 S1p 수용체의 조절제
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
CN103113303A (zh) * 2011-11-16 2013-05-22 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的氮杂环化合物
HUE042655T2 (hu) 2011-11-17 2019-07-29 Kbp Biosciences Co Ltd Nitrogént tartalmazó kondenzált gyûrûs vegyületek CRTH2 antagonistaként történõ alkalmazásra
JP6132853B2 (ja) * 2011-12-27 2017-05-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 全身性抗炎症反応を提供する、複数のプロスタグランジン受容体で作用する化合物
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
DK2970138T3 (en) 2013-03-13 2019-03-25 Canadian Blood Services PYRAZOLD DERIVATIVES AND THEIR USE THEREOF
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CN103265537B (zh) * 2013-05-14 2015-05-27 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
SG11202008560VA (en) 2018-03-08 2020-10-29 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020244968A1 (en) 2019-06-06 2020-12-10 Basf Se Fungicidal n-(pyrid-3-yl)carboxamides
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828914B1 (es) * 1969-04-11 1973-09-05
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
BE759032A (fr) * 1969-11-17 1971-04-30 Takeda Chemical Industries Ltd Acide 3,5-diphenyl-4-pyrazole acetique ou ses derives 1-substitues ou leurs esters
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
MXPA02004647A (es) * 1999-11-10 2002-10-31 Takeda Chemical Industries Ltd Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
JP2002348281A (ja) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd ５員複素環アルカン酸誘導体
JP2003073377A (ja) * 2001-06-20 2003-03-12 Takeda Chem Ind Ltd ５員複素環誘導体
JP2005508911A (ja) * 2001-09-25 2005-04-07 ファルマシア コーポレイション 置換ピラゾールの製造方法
US7211672B2 (en) * 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
US20070060596A1 (en) 2003-10-24 2007-03-15 Giblin Gerard M P Heterocyclyl compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525141D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP2040700B1 (en) 2006-06-06 2010-11-24 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
WO2008138876A1 (en) 2007-05-10 2008-11-20 Glaxo Group Limited Pyrazole derivatives as p2x7 modulators
PL2205569T3 (pl) * 2007-09-25 2012-08-31 Actimis Pharmaceuticals Inc Alkilotiopirymidyny jako antagoniści crth2
CA2700525A1 (en) 2007-09-25 2009-04-02 Actimis Pharmaceuticals, Inc. 2-s-benzyl substituted pyrimidines as crth2 antagonists
GB0719521D0 (en) * 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
ES2378755T3 (es) * 2008-07-15 2012-04-17 F. Hoffmann-La Roche Ag �?cidos aminotetrahidroindazoloacéticos
KR101906791B1 (ko) 2010-01-27 2018-10-11 베링거 인겔하임 인터내셔날 게엠베하 Ｃｒｔｈ２ 길항제로서의 피라졸 화합물

Also Published As

Publication number Publication date
EP2528901A1 (en) 2012-12-05
GEP20146177B (en) 2014-10-10
CY1116641T1 (el) 2017-03-15
TW201138769A (en) 2011-11-16
MX2012008361A (es) 2012-08-08
MA33937B1 (fr) 2013-01-02
PL2528901T3 (pl) 2015-11-30
JP2013518074A (ja) 2013-05-20
KR20170142217A (ko) 2017-12-27
MY160036A (en) 2017-02-15
US20120028938A1 (en) 2012-02-02
AU2011209286A1 (en) 2012-07-05
SG182684A1 (en) 2012-08-30
AP2012006313A0 (en) 2012-06-30
CA2788224A1 (en) 2011-08-04
AU2011209286B2 (en) 2016-02-11
EP2528901B9 (en) 2017-01-25
CO6511272A2 (es) 2012-08-31
EP2528901B1 (en) 2015-05-27
AR080032A1 (es) 2012-03-07
AP3360A (en) 2015-07-31
RS54176B1 (en) 2015-12-31
TWI499416B (zh) 2015-09-11
UY33201A (es) 2011-08-31
ZA201204335B (en) 2019-08-28
HRP20150898T1 (hr) 2015-10-09
HK1176062A1 (zh) 2013-07-19
ES2545865T3 (es) 2015-09-16
CN102884051B (zh) 2015-09-16
HUE025318T2 (en) 2016-02-29
US8791272B2 (en) 2014-07-29
CN104829535A (zh) 2015-08-12
DK2528901T3 (en) 2015-08-17
JP5658284B2 (ja) 2015-01-21
MX353000B (es) 2017-12-15
UA110025C2 (xx) 2015-11-10
TN2012000371A1 (en) 2014-01-30
BR112012018695A2 (pt) 2016-04-12
NZ600637A (en) 2014-07-25
CN102884051A (zh) 2013-01-16
CN108383789A (zh) 2018-08-10
KR101812000B1 (ko) 2017-12-26
CL2012001836A1 (es) 2012-11-23
CA2788224C (en) 2015-07-21
EA022280B1 (ru) 2015-12-30
WO2011092140A1 (en) 2011-08-04
SI2528901T1 (sl) 2015-10-30
PT2528901E (pt) 2015-10-13
EA201201050A1 (ru) 2013-02-28
IL220208A0 (en) 2012-07-31
IL220208A (en) 2016-11-30
KR101906791B1 (ko) 2018-10-11
KR20120117841A (ko) 2012-10-24

Similar Documents

Publication Publication Date Title
PE20121519A1 (es) Compuestos de pirazol como antagonistas de crth2
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20091386A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
PE20130601A1 (es) Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa
PE20140934A1 (es) Derivados de pirazol
PE20091725A1 (es) Activadores piridazinona de la glucoquinasa
NZ605528A (en) Ip receptor agonist heterocyclic compounds
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
MX353957B (es) Carboxamidas heterociclicas fungicidas.
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
EA201400622A1 (ru) Соединения 2-(замещенный-фенил)циклопентан-1,3-диона и их производные
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
MX2013011551A (es) Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales.
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
AR069480A1 (es) Derivados de 2-amino-pirimidina
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
PE20142282A1 (es) Nuevos derivados de aril-quinolina
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
PE20140968A1 (es) Derivados de benzamida sustituida
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
AR081821A1 (es) Antranilamidas sustituidas con triazol como plaguicidas

Legal Events

Date Code Title Description
FG Grant, registration